ADAR and mesothelioma: In summary, ADAR-dependent RNA editing and ADAR expression, via their involvement in regulating type 1 IFN signalling, represent potential biomarkers and targets for mesothelioma immunotherapy for the treatment of mesothelioma, as has been shown for other cancers.